Context: Acromegaly is caused by excessive GH secretion and IGF-I overproduction. The goals of treatment are to reduce GH and IGF-I values to normal and relieve the associated symptoms.
Objective: The purpose of this article was to demonstrate that an octreotide implant (84 mg) is safe and efficacious in patients with acromegaly who were responsive to prior monthly octreotide long-acting release (LAR) injections.
Design: This was a phase 3, open-label study. Before treatment, subjects received a stable monthly dose of octreotide LAR injections (10-40 mg) for ≥ 3 months. Randomization was in a 3:1 ratio to either a 6-month octreotide implant or monthly octreotide LAR injections.
Setting: This was a multicenter, international study conducted in private or institutional practices.
Subjects: Enrollment included 163 subjects (aged ≥ 18 years) with acromegaly.
Main Outcome Measure: The efficacy, safety, and tolerability of the octreotide implant during 24 weeks of treatment was evaluated.
Results: After 24 weeks, the success rate of the implant for maintenance of IGF-I and GH levels was 86% (95% confidence interval, 80.3%) compared with a rate of 84% (95% confidence interval, 73.8%) for octreotide LAR. Serum octreotide concentrations after implant insertion increased within 8 days and peaked between days 14 and 28. The overall safety of the octreotide implant and octreotide LAR were similar. Diarrhea and headache were more frequent with the implant, whereas cholecystitis and hypertension were more frequent with octreotide LAR.
Conclusions: In this pivotal phase 3 study, the octreotide implant maintained reduced blood levels of GH and IGF-I with continuous octreotide release over 6 months, which was well tolerated.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1210/jc.2013-2262 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Recent advances in the treatment of refractory gastrointestinal angiodysplasia.
United European Gastroenterol J
October 2024
Sorbonne University, Center for Digestive Endoscopy, Saint Antoine Hospital, AP HP, Paris, France.
Article Synopsis
- - Gastrointestinal angiodysplasia (GIA) is a prevalent, acquired vascular issue in the digestive tract, often leading to significant bleeding and requiring repeat treatments such as transfusions or endoscopies.
- - Recent studies focus on non-endoscopic options for treating refractory GIA, highlighting the effectiveness of aortic valve replacement in cases of Heyde syndrome and the use of anti-angiogenic drugs like Octreotide and Thalidomide.
- - Future advancements in understanding the underlying mechanisms of GIA could pave the way for the development of new, targeted treatments.
Carcinoid heart disease: a potentially fatal complication of carcinoid syndrome.
BMJ Case Rep
December 2023
Cardiology/Department of Internal medicine, Wayne State University/ Detroit Medical Center, Detroit, Michigan, USA.
Carcinoid heart disease is a unique and serious cardiac complication of the neuroendocrine tumour that affects the right side of the heart, especially the tricuspid and pulmonic valves, eventually causing right heart failure. We present a middle-aged man with a history of well-differentiated neuroendocrine tumours of the small intestine with extensive metastases to the liver, mesentery and spine who is receiving monthly octreotide therapy. He presented with generalised fatigue, severe ascites and worsening dyspnoea.
View Article and Find Full Text PDFHedinger Syndrome-Lessons Learnt: A Single-Center Experience.
J Cardiovasc Dev Dis
October 2023
Department of Thoracic and Cardiovascular Surgery, West-German Heart and Vascular Centre, 45147 Essen, Germany.
Background: Hedinger syndrome (HS) or carcinoid heart disease (CD) is a rare and challenging manifestation of malignant neuroendocrine tumours (NETs) involving the heart. We aimed to report our experience with surgical strategies and midterm results in HS patients.
Methods: Eleven patients (58 ± 11 (range 41 to 79 years); 5 females) with HS who underwent cardiac surgery in our department between 07/2005 and 05/2023 were analysed.
Addition of Peptide Receptor Radiotherapy to Immune Checkpoint Inhibition Therapy Improves Outcomes in Neuroendocrine Tumors.
J Nucl Med
July 2023
Athinoula A. Martinos Center for Biomedical Imaging, Department of Radiology, Massachusetts General Hospital, Charlestown, Massachusetts;
Neuroendocrine tumors (NETs) are often diagnosed in advanced stages. Despite the advances in treatment approaches, including somatostatin analogs and peptide receptor radionuclide therapy (PRRT), these patients have no curative treatment option. Moreover, immunotherapy often yields modest results in NETs.
View Article and Find Full Text PDFGastrointestinal bleeding in patients with continuous-flow left ventricular assist devices: A comprehensive review.
Artif Organs
January 2023
Division of Cardiology, Texas Tech University Health Sciences Center, Lubbock, Texas, USA.
Background: Gastrointestinal bleeding is a major cause of morbidity that plagues the quality of life of patients supported on contemporary continuous-flow left ventricular assist devices (CF-LVADs). Despite benefits in survival and the nearly 50% reduction in complications provided by CF-LVADs, bleeding remains one of the most frequent adverse events with CF-LVAD implants. The CF-LVADs cause an increased risk of bleeding mainly due to the activation of the coagulation cascade.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!